Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Good morning. Please take some time today to read this story from my colleague Eric Boodman, who spent a year investigating how doctors are pushing sickle cell patients to get unwanted sterilizations. This is the first story in a new series from STAT called Coercive Care.
The need-to-know this morning
- AstraZeneca said it plans to deliver $80 billion in total revenue by 2030, up from $45.8 billion last year. The new growth will be fueled by the launch of 20 new medicines before the end of the decade, the pharma giant said at an investor event.
- Bristol Myers Squibb said the FDA’s decision date for a subcutaneously injected version of its cancer medicine Opdivo was moved forward to Dec. 29. Previously, it was Feb. 28, 2025. The new Opdivo formulation is made using drug-delivery technology from Halozyme.
- GSK said a new asthma treatment that could be administered just once every six months succeeded in two Phase 3 trials.
The immunology financing streak continues
AltruBio said this morning that it raised $225 million in a Series B round to advance a drug for the treatment of ulcerative colitis, an autoimmune condition.
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.
Already have an account? Log in
Already have an account? Log in
About the Author Reprints
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect